Drug Shortage Report for MYLAN-NAPROXEN/ESOMEPRAZOLE MR
Report ID | 203214 |
Drug Identification Number | 02443449 |
Brand name | MYLAN-NAPROXEN/ESOMEPRAZOLE MR |
Common or Proper name | NAPROXEN/ESOMEPRAZOLE MR |
Company Name | MYLAN PHARMACEUTICALS ULC |
Market Status | MARKETED |
Active Ingredient(s) | ESOMEPRAZOLE NAPROXEN |
Strength(s) | 20MG 500MG |
Dosage form(s) | TABLET (IMMEDIATE AND DELAYED-RELEASE) |
Route of administration | ORAL ORAL |
Packaging size | 60BT |
ATC code | M01AE |
ATC description | ANTIINFLAMMATORY/ANTIRHEUMATIC PROD.,NON-STEROIDS |
Reason for shortage | Shortage of an inactive ingredient or component. |
Anticipated start date | 2023-09-04 |
Actual start date | 2023-08-24 |
Estimated end date | 2023-09-29 |
Actual end date | 2023-09-29 |
Shortage status | Resolved |
Updated date | 2023-10-03 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 85 ADVANCE ROAD ETOBICOKE, ONTARIO CANADA M8Z 2S6 |
Company contact information | Mylan Pharmaceuticals ULC, 85 Advance Road, Etobicoke, ON, M8Z 2S6 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2023-10-03 | French | Compare |
v8 | 2023-10-03 | English | Compare |
v7 | 2023-09-11 | French | Compare |
v6 | 2023-09-11 | English | Compare |
v5 | 2023-09-06 | French | Compare |
v4 | 2023-09-06 | English | Compare |
v3 | 2023-09-05 | English | Compare |
v2 | 2023-08-29 | French | Compare |
v1 | 2023-08-29 | English | Compare |
Showing 1 to 9 of 9